Loading
The phase 3 trials that will decide whether alpha-emitting PSMA drugs become the next step after Pluvicto.
AlphaBreak and AcTION, led by trial NCT06402331, are the phase 3 trials that will decide whether alpha-emitting PSMA drugs become the next step after Pluvicto in PSMA-positive metastatic castration-resistant prostate cancer. AlphaBreak tests FPI-2265, an actinium-225 PSMA-I&T agent from AstraZeneca and Fusion, after lutetium PSMA therapy, while Novartis' AcTION programme tests actinium-225 PSMA-617 in post-lutetium and lutetium-naive settings, and Bayer's PAnTHA phase 1 of 225Ac-PSMA-Trillium reported at ASCO GU 2026; the record lists an enrolment target of 600. OnCo links them to targeted alpha therapy, the actinium-225 PSMA agents record, and to Fusion, AstraZeneca, Novartis and Bayer. Both are recruiting with no results, dry mouth and actinium-225 supply are the constraints, and whether alpha emitters help after lutetium is the question they exist to answer.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Actinium-225 PSMA agents, Targeted alpha therapy, Prostate cancer.
Shares Actinium-225 PSMA agents, AstraZeneca, Prostate cancer.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, AstraZeneca, Prostate cancer.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Actinium-225 PSMA agents, Targeted alpha therapy, Prostate cancer.